JP Morgan Chase’s Gain Therapeutics GANX Stock Holding History

JP Morgan Chase’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.06K	Buy	+1,700	New	+$3.7K	﹤0.01%	6950
2025 Q4	–	Sell	-26,280	Closed	-$46.5K	–	7543
2025 Q3	$46.5K	Buy	+26,280	New	+$44.3K	﹤0.01%	6257
2023 Q3	–	Sell	-6	Closed	-$27	–	7551
2023 Q2	$27	Buy	+6	New	+$29	﹤0.01%	6774
2022 Q4	–	Sell	-594	Closed	-$2K	–	6708
2022 Q3	$2K	Buy	+594	New	+$2.23K	﹤0.01%	6249

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's GANX Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Gain Therapeutics (GANX) in Q1 2026: 1,700 shares worth $3.06K. The stake represents ﹤0.01% of the portfolio and ranks #6950 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in GANX as recently as Q3 2025.

JP Morgan Chase first reported a position in GANX in Q3 2022 and has held it in 4 quarters since. The position peaked at $46.5K in Q3 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

JP Morgan Chase held 1,700 shares of Gain Therapeutics worth $3.06K as of Q1 2026.
Gain Therapeutics was a new JP Morgan Chase position in Q1 2026.
Gain Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6950 holding.
JP Morgan Chase first reported a position in Gain Therapeutics in Q3 2022 and has held it in 4 quarters since.
JP Morgan Chase's Gain Therapeutics position peaked at $46.5K in Q3 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.